PT1034001E - Terapia por bloqueio das celulas cd154 contra o sindroma inibidor de proteinas terapeuticas - Google Patents

Terapia por bloqueio das celulas cd154 contra o sindroma inibidor de proteinas terapeuticas

Info

Publication number
PT1034001E
PT1034001E PT98931391T PT98931391T PT1034001E PT 1034001 E PT1034001 E PT 1034001E PT 98931391 T PT98931391 T PT 98931391T PT 98931391 T PT98931391 T PT 98931391T PT 1034001 E PT1034001 E PT 1034001E
Authority
PT
Portugal
Prior art keywords
protein inhibitor
therapeutic protein
therapy against
cell lock
inhibitor syndrome
Prior art date
Application number
PT98931391T
Other languages
English (en)
Inventor
Adelman Burt
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of PT1034001E publication Critical patent/PT1034001E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PT98931391T 1997-06-20 1998-06-19 Terapia por bloqueio das celulas cd154 contra o sindroma inibidor de proteinas terapeuticas PT1034001E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20

Publications (1)

Publication Number Publication Date
PT1034001E true PT1034001E (pt) 2004-12-31

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98931391T PT1034001E (pt) 1997-06-20 1998-06-19 Terapia por bloqueio das celulas cd154 contra o sindroma inibidor de proteinas terapeuticas

Country Status (25)

Country Link
US (1) US20020119151A1 (pt)
EP (1) EP1034001B1 (pt)
JP (1) JP2002504910A (pt)
KR (1) KR100567998B1 (pt)
CN (2) CN1261285A (pt)
AT (1) ATE272408T1 (pt)
AU (1) AU733062B2 (pt)
BG (1) BG64436B1 (pt)
BR (1) BR9810755A (pt)
CA (1) CA2294138A1 (pt)
CZ (1) CZ295805B6 (pt)
DE (1) DE69825473T2 (pt)
EA (1) EA002512B1 (pt)
EE (1) EE9900587A (pt)
ES (1) ES2226152T3 (pt)
HK (1) HK1031825A1 (pt)
HU (1) HUP0002048A3 (pt)
IL (1) IL133305A0 (pt)
IS (1) IS2097B (pt)
NO (1) NO996274L (pt)
NZ (1) NZ502051A (pt)
PT (1) PT1034001E (pt)
SK (1) SK285962B6 (pt)
TR (1) TR199903141T2 (pt)
WO (1) WO1998058672A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142069A0 (en) * 1998-09-21 2002-03-10 Genetics Inst Methods of downmodulating the immune response to therapeutic proteins
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030306A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
NZ544486A (en) * 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
AU2006247134B2 (en) 2005-05-18 2012-05-10 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
JP2001508450A (ja) * 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物の治療学的投与の方法

Also Published As

Publication number Publication date
EP1034001B1 (en) 2004-08-04
KR100567998B1 (ko) 2006-04-07
HK1031825A1 (en) 2001-06-29
HUP0002048A2 (hu) 2000-10-28
DE69825473T2 (de) 2005-08-04
SK285962B6 (sk) 2007-12-06
CA2294138A1 (en) 1998-12-30
US20020119151A1 (en) 2002-08-29
NZ502051A (en) 2001-04-27
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
AU8153698A (en) 1999-01-04
ATE272408T1 (de) 2004-08-15
TR199903141T2 (xx) 2000-09-21
EA002512B1 (ru) 2002-06-27
KR20010013964A (ko) 2001-02-26
NO996274D0 (no) 1999-12-17
BG104092A (en) 2000-10-31
EA200000059A1 (ru) 2000-08-28
BG64436B1 (en) 2005-02-28
CZ458899A3 (cs) 2000-04-12
ES2226152T3 (es) 2005-03-16
NO996274L (no) 2000-02-18
JP2002504910A (ja) 2002-02-12
EP1034001A1 (en) 2000-09-13
DE69825473D1 (de) 2004-09-09
WO1998058672A1 (en) 1998-12-30
CZ295805B6 (cs) 2005-11-16
IL133305A0 (en) 2001-04-30
IS2097B (is) 2006-04-12
CN1651071A (zh) 2005-08-10
CN1261285A (zh) 2000-07-26
SK180399A3 (en) 2000-06-12
IS5274A (is) 1999-11-26
AU733062B2 (en) 2001-05-03
BR9810755A (pt) 2000-08-15

Similar Documents

Publication Publication Date Title
PT1034001E (pt) Terapia por bloqueio das celulas cd154 contra o sindroma inibidor de proteinas terapeuticas
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
ZA200005475B (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor.
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
WO1999043344A3 (en) Matrix protein compositions for wound healing
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU4726797A (en) Prophylactic/remedial agent
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
WO2002026249A3 (en) Methods for inhibition of viral infection
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
WO2003015714A3 (en) Compositions and therapeutic methods for viral infection
IL136225A0 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
MY118982A (en) Method of reducing tissue damage associated with ischemia